6-Chloro-MDA
| Clinical data | |
|---|---|
| Other names | 6-Cl-MDA; 6-Chloro-3,4-methylenedioxyamphetamine; 2-Chloro-4,5-methylenedioxyamphetamine; 2-Chloro-4,5-MDA; 2-Cl-4,5-MDA; C-MDA; 6CL-MDA |
| Routes of administration | Oral[1] |
| Drug class | Psychoactive drug |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C10H12ClNO2 |
| Molar mass | 213.66 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
6-Chloro-MDA, also known as 6-chloro-3,4-methylenedioxyamphetamine or as 2-chloro-4,5-methylenedioxyamphetamine (2-Cl-4,5-MDA), is a psychoactive drug of the phenethylamine, amphetamine, and MDxx families related to 3,4-methylenedioxyamphetamine (MDA).[1][2] It is the 6-chloro derivative of MDA.[1] The drug has an active dose of 160 mg orally and a duration of approximately 8 hours.[1] It is a weak monoamine oxidase inhibitor (MAOI).[3][4][5] 6-Chloro-MDA was first described in the scientific literature by 1970.[2][6] The properties of 6-chloro-MDA in humans were described by Daniel Trachsel and colleagues in 2013 via personal communication with P. Rausch in 2009.[1]
See also
References
- ^ a b c d e Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine: von der Struktur zur Funktion [Phenethylamines: From Structure to Function]. Nachtschatten-Science (in German) (1st ed.). Solothurn: Nachtschatten-Verlag. pp. 830, 878. ISBN 978-3-03788-700-4. OCLC 858805226. Archived from the original on 21 August 2025.
Die halogenierten Verbindungen 6F-MDA (294), 6CL-MDA (295) und 6BR-MDA (296; 2-BR-4,5-MDA) sind bekannte Verbindungen. [...] Das Chloroanalogon 6CL-MDA (295) war in ersten Tests im Menschen vergleichbar aktiv Wie 2Me-MDA (292) (160mg, rund 8h Dauer) [140], und 6BR-MDA (296; 2-BR-4,5-MDA) erwies sich bei Dosierungen von bis zu 350mg als inaktiv [8, 134]. [...] 295; 6CL-MDA; 160mg; 8h. [...] [140] P. Rausch. Persönliche Mitteilung, 2009.
- ^ a b Shulgin A, Manning T, Daley P (2011). The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds. Vol. 1. Berkeley: Transform Press. p. 347. ISBN 978-0-9630096-3-0.
2-Cl-4,5-MDA [27164-29-0] (2,3) [...] (2) Synthesized as a potential psychedelic drug (Hellot et al., 1970a). (3) MDA, and three analogues with a chloro, bromo, or a nitro group in the 6-position, were experimentally oxidized by differential pulse voltammetry (Squella et al., 1993).
- ^ Reyes-Parada M, Iturriaga-Vasquez P, Cassels BK (2019). "Amphetamine Derivatives as Monoamine Oxidase Inhibitors". Frontiers in Pharmacology. 10 1590. doi:10.3389/fphar.2019.01590. PMC 6989591. PMID 32038257.
- ^ Scorza MC, Carrau C, Silveira R, Zapata-Torres G, Cassels BK, Reyes-Parada M (December 1997). "Monoamine oxidase inhibitory properties of some methoxylated and alkylthio amphetamine derivatives: structure-activity relationships". Biochemical Pharmacology. 54 (12): 1361–1369. doi:10.1016/s0006-2952(97)00405-x. PMID 9393679.
- ^ Vallejos G, Rezende MC, Cassels BK (February 2002). "Charge-transfer interactions in the inhibition of MAO-A by phenylisopropylamines--a QSAR study". Journal of Computer-Aided Molecular Design. 16 (2): 95–103. Bibcode:2002JCAMD..16...95V. doi:10.1023/a:1016344030772. PMID 12188024.
- ^ Hellot J, Violland-Duperret N, Pacheco H (1970). "Psychotropes potentiels VI. Synthèse de nouveaux mescalinoïdes". Chimie Therapeutique. 5 (1): 55–64.